Development of an HPLC-MS/MS Method for Quantitative Determination of Rivaroxaban in Human Blood Serum

T. A. Rodina; E. S. Mel’nikov; A. A. Aksenov; S. A. Belkov; A. V. Sokolov; A. B. Prokof’ev; G. V. Ramenskaya

doi:10.1007/s11094-018-1824-3

Development of an HPLC-MS/MS Method for Quantitative Determination of Rivaroxaban in Human Blood Serum

Autores: Rodina T.¹, Mel’nikov E.¹, Aksenov A.¹, Belkov S.¹, Sokolov A.¹, Prokof’ev A.¹, Ramenskaya G.¹
Afiliações:
1. Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Edição: Volume 52, Nº 4 (2018)
Páginas: 372-377
Seção: Article
URL: https://journals.rcsi.science/0091-150X/article/view/245191
DOI: https://doi.org/10.1007/s11094-018-1824-3
ID: 245191

Citar

Texto integral

Acesso aberto
Acesso é fechado

Acesso está concedido
Acesso é fechado

Somente assinantes

Resumo
Sobre autores
Bibliografia
Estatísticas

Resumo

An HPLC-MS/MS method for determination of rivaroxaban in human blood serum was developed. Sample preparation included protein precipitation by MeOH followed by centrifugation and dilution with deionized H₂O. The developed procedure had simple sample preparation, a short analysis time, and a wide analytical range (1.00 to 1,000.00 ng/mL). The procedure was convenient for routine bioanalytical studies, in particular, for therapeutic drug monitoring.